Insurers rarely require prior authorization for opioids; court of appeals voids J&J win in Advil ads suit; new California law to address drug pricing
Consumers younger than the age of 45 were most likely to use an app developed by their health plan.
Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
CVS formulary changes lifted Tresiba sales; Novartis licenses NASH drug; FDA is building digital health unit
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Dr. Vidya Raman-Tangella is head of the UHC innovation center of excellence.
Jay Rajda is chief clinical transformation officer and senior medical director for clinical innovation and health and clinical services at Aetna.
Geeta Wilson is VP of consumer experience at Humana.
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
The health insurer partnered with Microsoft to use VR and AR technology to gather biometric data.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
One pharmacy director would like to see a lot more comparative data about new therapies.
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval
Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant
Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks
Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market
Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics
Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus
New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit
AHIP study says half of orphan-drug usage is for non-orphan indications; Studies of GSK weight-loss pill underestimated side effects; ViiV starts HIV trial
The campaign will run in an integrated digital marketing format using channels such as Facebook, Twitter, and Youtube.
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO
Her hire comes as the insurance giant is merging with Humana in a $37 billion deal.
UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
The health insurer uses Dirty Dancing, Alien, and Rocky to help consumers navigate the U.S. health system.
Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth